GlassScriptPhysician profile
Charlene Vitale
NPI 1720099856
$8,934.91
in general payments reported to CMS, 2019-2025
39 companies · $2,420 in 2025
The $2,420 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $384 · 2021: $1,021 · 2022: $1,276 · 2023: $1,338 · 2024: $2,142 · 2025: $2,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,869 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,868.75 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,983.92 | 2019-2025 | Vraylar, Ubrelvy, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,370.45 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Amgen INC. | $1,097.34 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $1,010.84 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $744.79 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $549.18 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $277.99 | 2019-2021 | |
| Astellas Pharma US INC | $199.16 | 2019-2021 | |
| Abbott Laboratories | $178.25 | 2021-2023 | Freestyle Libre 2 |
| Lilly USA, LLC | $164.12 | 2021-2024 | Mounjaro, Zepbound |
| Amneal Pharmaceuticals LLC | $156.13 | 2022-2024 | Unithroid |
| Amarin Pharma, INC. | $146.89 | 2020-2022 | |
| Glaxosmithkline, LLC. | $145.66 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.46 | 2021-2025 | Jardiance, Synjardy |
| Ascendis Pharma Endocrinology INC | $71.51 | 2025 | Yorvipath |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Vitale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.